Page 1 | Search Results | ASH Clinical News | American Society of Hematology

1-20 of 129

Sort by

Sort Order Select

News

Dual-Targeting BCMA, CD19 CAR T-Cell Therapy Shows 100% Response in NDMM

Katie Robinson

View News titled, Dual-Targeting BCMA, CD19 CAR T-Cell Therapy Shows 100% Response in NDMM

News

Delayed Obinutuzumab Enhances Safety in First-Line Acalabrutinib Plus Venetoclax for CLL

Katie Robinson

View News titled, Delayed Obinutuzumab Enhances Safety in First-Line Acalabrutinib Plus Venetoclax for CLL

News

Preclinical Study Shows Potential of Menin Inhibition in Myeloproliferative Neoplasms

Katie Robinson

Abstract

View News titled, Preclinical Study Shows Potential of Menin Inhibition in Myeloproliferative Neoplasms

News

BTK Degrader Shows Tolerable Safety, High Responses in Phase I Study of R/R CLL/SLL

Katie Robinson

View News titled, BTK Degrader Shows Tolerable Safety, High Responses in Phase I Study of R/R CLL/SLL

News

Is Targeted Therapy for a Fixed Duration More Effective Than Chemoimmunotherapy in Untreated CLL?

Katie Robinson

Abstract

View News titled, Is Targeted Therapy for a Fixed Duration More Effective Than Chemoimmunotherapy in Untreated CLL?

News

Rusfertide Shows Durable Responses in Phase III Study of Polycythemia Vera

Katie Robinson

Abstract

View News titled, Rusfertide Shows Durable Responses in Phase III Study of Polycythemia Vera

News

Early Data Show Mutant CALR-Specific Monoclonal Antibody Well Tolerated in Myelofibrosis

Katie Robinson

Abstract

View News titled, Early Data Show Mutant CALR-Specific Monoclonal Antibody Well Tolerated in Myelofibrosis

News

Should Early-Stage MCL Be Treated Aggressively or Not?

Katie Robinson

Abstract

View News titled, Should Early-Stage MCL Be Treated Aggressively or Not?

News

Phase II Study Confirms Pemigatinib Efficacy, Tolerability in Myeloid, Lymphoid Neoplasms With FGFR1 Rearrangements

Katie Robinson

Abstract

View News titled, Phase II Study Confirms Pemigatinib Efficacy, Tolerability in Myeloid, Lymphoid Neoplasms With FGFR1 Rearrangements

News

Experts to Discuss Co-Managing Complex Hematologic Issues During Pregnancy, Delivery

Katie Robinson

Abstract

View News titled, Experts to Discuss Co-Managing Complex Hematologic Issues During Pregnancy, Delivery

News

Watch-and-Wait Approach May Allow Certain Patients With JMML to Avoid HCT

Katie Robinson

Abstract

View News titled, Watch-and-Wait Approach May Allow Certain Patients With JMML to Avoid HCT

News

Erythroid-Predominant MDS Shows Specific Genetic Features, Poor Outcomes With Venetoclax

Katie Robinson

Abstract

View News titled, Erythroid-Predominant MDS Shows Specific Genetic Features, Poor Outcomes With Venetoclax

News

Phase I R/R MM Study of Talquetamab Plus Daratumumab Achieves Safety Endpoint, Durable Responses

Katie Robinson

Abstract

View News titled, Phase I R/R MM Study of Talquetamab Plus Daratumumab Achieves Safety Endpoint, Durable Responses

News

EMD Linked to Severe Toxicities After CAR T-Cell Therapy in MM

Katie Robinson

Abstract

View News titled, EMD Linked to Severe Toxicities After CAR T-Cell Therapy in MM

News

IMS-IMWG Releases New Consensus Definition of High-Risk MM Based on Genomics

Katie Robinson

Abstract

View News titled, IMS-IMWG Releases New Consensus Definition of High-Risk MM Based on Genomics

News

Single-Run NGS Approach for MDS Improves Diagnostic Accuracy, Workflow in Resource-Constrained Setting

Katie Robinson

Abstract

View News titled, Single-Run NGS Approach for MDS Improves Diagnostic Accuracy, Workflow in Resource-Constrained Setting

News

Nurse-Led Multidisciplinary Pathway Developed to Optimize Patient Journey in Acquired Hemophilia A

Katie Robinson

Abstract

View News titled, Nurse-Led Multidisciplinary Pathway Developed to Optimize Patient Journey in Acquired Hemophilia A

News

Long-Term Data Confirm Early Rituximab Monotherapy Delays New Treatment in Advanced, Asymptomatic LTBFL

Katie Robinson

Abstract

View News titled, Long-Term Data Confirm Early Rituximab Monotherapy Delays New Treatment in Advanced, Asymptomatic LTBFL

News

Immunoglobulin Replacement Therapy in MM May Reduce Risk, Severity of Infections, Development of Hypogammaglobulinemia

Katie Robinson

Abstract

View News titled, Immunoglobulin Replacement Therapy in MM May Reduce Risk, Severity of Infections, Development of Hypogammaglobulinemia

News

Marstacimab Shows Long-Term Efficacy in Severe Hemophilia A, B Without Inhibitors

Katie Robinson

Abstract

View News titled, Marstacimab Shows Long-Term Efficacy in Severe Hemophilia A, B Without Inhibitors

Update search

NARROW

Publications

Format

Topics

Date

Availability

Dual-Targeting BCMA, CD19 CAR T-Cell Therapy Shows 100% Response in NDMM

Delayed Obinutuzumab Enhances Safety in First-Line Acalabrutinib Plus Venetoclax for CLL

Preclinical Study Shows Potential of Menin Inhibition in Myeloproliferative Neoplasms

BTK Degrader Shows Tolerable Safety, High Responses in Phase I Study of R/R CLL/SLL

Is Targeted Therapy for a Fixed Duration More Effective Than Chemoimmunotherapy in Untreated CLL?

Rusfertide Shows Durable Responses in Phase III Study of Polycythemia Vera

Early Data Show Mutant CALR-Specific Monoclonal Antibody Well Tolerated in Myelofibrosis

Should Early-Stage MCL Be Treated Aggressively or Not?

Phase II Study Confirms Pemigatinib Efficacy, Tolerability in Myeloid, Lymphoid Neoplasms With FGFR1 Rearrangements

Experts to Discuss Co-Managing Complex Hematologic Issues During Pregnancy, Delivery

Watch-and-Wait Approach May Allow Certain Patients With JMML to Avoid HCT

Erythroid-Predominant MDS Shows Specific Genetic Features, Poor Outcomes With Venetoclax

Phase I R/R MM Study of Talquetamab Plus Daratumumab Achieves Safety Endpoint, Durable Responses

EMD Linked to Severe Toxicities After CAR T-Cell Therapy in MM

IMS-IMWG Releases New Consensus Definition of High-Risk MM Based on Genomics

Single-Run NGS Approach for MDS Improves Diagnostic Accuracy, Workflow in Resource-Constrained Setting

Nurse-Led Multidisciplinary Pathway Developed to Optimize Patient Journey in Acquired Hemophilia A

Long-Term Data Confirm Early Rituximab Monotherapy Delays New Treatment in Advanced, Asymptomatic LTBFL

Immunoglobulin Replacement Therapy in MM May Reduce Risk, Severity of Infections, Development of Hypogammaglobulinemia

Marstacimab Shows Long-Term Efficacy in Severe Hemophilia A, B Without Inhibitors

ASH Publications

American Society of Hematology

Update search

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only